Supernus to Present at Two November Investor Conferences
November 11 2020 - 11:13PM
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases, today announced
that the Company's management will present an overview and update,
as well as host investor meetings, at the following virtual
investor conferences in November 2020.
Stifel 2020 Healthcare ConferenceDate: Monday, November 16,
2020Presentation Time: 9:20 a.m. ET
Jefferies Virtual London Healthcare ConferenceDate: Tuesday,
November 17, 2020Presentation Time: 1:45 p.m. ET
A live webcast of the presentation can be accessed by visiting
Events & Presentations in the Investor Relations section on the
Company's website at www.supernus.com. An archived replay of this
webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company
focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases. The Company
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR®
(extended-release oxcarbazepine) for the treatment of epilepsy;
APOKYN® (apomorphine hydrochloride injection) for the acute
treatment of hypomobility in advanced Parkinson’s disease (PD);
MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical
dystonia and treatment of chronic sialorrhea in adults; and XADAGO®
(safinamide) as an adjunctive treatment to levodopa/carbidopa in PD
patients with hypomobility. The Company is also developing several
product candidates to address large market opportunities in the CNS
market, including SPN-812 for the treatment of ADHD; SPN-830
(apomorphine infusion pump) for the continuous treatment of motor
fluctuations (“on-off” episodes) in PD; SPN-820 for
treatment-resistant depression; and SPN-817 for the treatment of
epilepsy.
See full Prescribing Information for our products here: Trokendi
XR, Oxtellar XR, APOKYN, MYOBLOC, and XADAGO.
All trademarks are the property of their respective owners.
CONTACTS:Jack A. Khattar, President and CEOJim
Kelly, Executive Vice President and CFOSupernus Pharmaceuticals,
Inc.Tel: (301) 838-2591
or
INVESTOR CONTACT:Peter VozzoWestwicke, an ICR
CompanyOffice: (443) 213-0505Mobile: (443) 377-4767Email:
peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024